Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer

Bibliographic Details
Main Authors:	Thomas Kunzke, Fabian T. Hölzl, Verena M. Prade, Achim Buck, Katharina Huber, Annette Feuchtinger, Karolin Ebert, Gwen Zwingenberger, Robert Geffers, Stefanie M. Hauck, Ivonne Haffner, Birgit Luber, Florian Lordick, Axel Walch
Format:	Article
Language:	English
Published:	Wiley 2021-09-01
Series:	Clinical and Translational Medicine
Online Access:	https://doi.org/10.1002/ctm2.547

Similar Items

De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry
by: Verena M. Prade, et al.
Published: (2020-06-01)

MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
by: Karolin Ebert, et al.
Published: (2019-01-01)

Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines
by: Simone Keller, et al.
Published: (2018-04-01)

Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
by: Karolin Ebert, et al.
Published: (2020-10-01)

Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction
by: Thomas Kunzke, et al.
Published: (2020-02-01)

Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer
by: Maelle Le Thiec, et al.
Published: (2020-06-01)

Prognostic impact of pretherapeutic gamma-glutamyltransferase on patients with nasopharyngeal carcinoma.
by: Yue-Feng Wen, et al.
Published: (2017-01-01)

The Influence of Pretherapeutic and Preoperative Sarcopenia on Short-Term Outcome after Esophagectomy
by: Johanna Grün, et al.
Published: (2020-11-01)

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell lines.
by: Elba Raimúndez, et al.
Published: (2020-03-01)

Prognostic relevance of pretherapeutic gamma-glutamyltransferase in patients with primary metastatic breast cancer.
by: Christine Staudigl, et al.
Published: (2015-01-01)

Evaluation of a strategy using pretherapeutic fiducial marker placement to avoid missing liver metastases
by: V. Kepenekian, et al.
Published: (2019-06-01)

Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia
by: Ditte J. A. Løhmann, et al.
Published: (2019-11-01)

Identification of small molecule inhibitors of regulator of G protein signaling proteins for pretherapeutic development for treatment of multiple pathologies
by: Bodle, Christopher Ralph
Published: (2017)

Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin’s lymphoma
by: Julian M. M. Rogasch, et al.
Published: (2018-05-01)

Pretherapeutic Imaging for Axillary Staging in Breast Cancer: A Systematic Review and Meta-Analysis of Ultrasound, MRI and FDG PET
by: Morwenn Le Boulc’h, et al.
Published: (2021-04-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer
by: Tomoyuki Tatenuma, et al.
Published: (2019-01-01)

Whole-body MRI versus 18F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis
by: Wang D, et al.
Published: (2018-06-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

High-throughput identification and characterization of novel inhibitors of Regulator of G Protein Signaling 17 as pretherapeutic leads for the treatment of lung and prostate cancers
by: Mackie, Duncan Ian
Published: (2014)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
by: Tatiana Strava Corrêa, et al.
Published: (2018-05-01)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
by: Zhou Qiong, et al.
Published: (2020-07-01)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
by: Daisuke Kotani, et al.
Published: (2021-01-01)

HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
by: Tiziana Triulzi, et al.
Published: (2019-01-01)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
by: Celia Nieto, et al.
Published: (2019-06-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Gabriel L. Fiszman, et al.
Published: (2011-01-01)

Reorienting the Fab domains of trastuzumab results in potent HER2 activators.
by: Justin M Scheer, et al.
Published: (2012-01-01)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
by: Oostra DR, et al.
Published: (2014-07-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
by: Alice Indini, et al.
Published: (2021-04-01)

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation
by: Yong-Jin Park, et al.
Published: (2021-04-01)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
by: Han Y, et al.
Published: (2019-05-01)

Pretherapeutic plasma pro- and anti- inflammatory mediators are related to high risk of oral mucositis in pediatric patients with acute leukemia: a prospective cohort study.
by: Ying Ye, et al.
Published: (2013-01-01)

In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) Against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474
by: Priyanka Bapat, et al.
Published: (2021-04-01)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021-05-01)